Lv53
1550 积分 2020-12-07 加入
Changing treatment patterns for hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results–Medicare study
13天前
已完结
The combination of FOLFOX4 and bevacizumab may enable salvage surgery of unresectable liver metastases in colon cancer
18天前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
19天前
已完结
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
27天前
已完结
Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial
1个月前
已关闭
A new standard for HCC: The high stakes of TACE-immunotherapy combinations
1个月前
已完结
Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses
1个月前
已完结
Improved survival outcome of curative liver resection for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma in the era of tyrosine kinase inhibitors
1个月前
已完结
Impact of compliance to postoperative regular follow-up on long-term prognosis after curative resection for hepatocellular carcinoma: A multicenter analysis
1个月前
已完结
Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors
1个月前
已完结
皖公网安备34019202002308
